Want to see IN:MEDANTA full AI Analyst Report?
Top Page
Global Health Limited
(MEDANTA)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹1,564.00
▲(14.13% Upside)
Action:Upgraded
Date:08/17/26
The score is primarily supported by strong financial momentum (growth and profitability) and constructive technical trend signals, but it is held back by stretched valuation (high P/E and minimal dividend yield) and the recent deterioration in free cash flow (negative in 2026).
Positive Factors
Sustained Revenue and Profit Growth
Consistent multi-year revenue expansion and stronger profitability indicate growing demand for Medanta’s healthcare services and improved operating scale, supporting earnings resilience over the medium term.
Negative Factors
Negative Latest Free Cash Flow
The shift to negative free cash flow reduces near-term financial flexibility and indicates that investment or spending has outpaced internally generated cash, potentially increasing reliance on funding while expansion continues.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue and Profit Growth
Consistent multi-year revenue expansion and stronger profitability indicate growing demand for Medanta’s healthcare services and improved operating scale, supporting earnings resilience over the medium term.
Read all positive factors
Global Health Limited (MEDANTA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹389.21B
Dividend Yield0.07%
Average Volume (3M)54.10K
Price to Earnings (P/E)69.9
Beta (1Y)0.66
Revenue Growth21.27%
EPS Growth4.09%
CountryIN
Employees12,600
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)20.71
Shares Outstanding268,871,800
10 Day Avg. Volume40,007
30 Day Avg. Volume54,103
Financial Highlights & Ratios
PEG Ratio2.98
Price to Book (P/B)6.52
Price to Sales (P/S)5.86
P/FCF Ratio-114.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,660.00Price Target Upside21.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)26.65
Revenue Forecast (FY)₹53.10B
Global Health Limited Business Overview & Revenue Model
Company Description
Operating throughout India, Global Health Limited, known by its Medanta brand, stands as a prominent multi-specialty tertiary care provider. The company delivers a comprehensive suite of healthcare services, with particular expertise in cardiology...
How the Company Makes Money
Medanta primarily makes money by delivering healthcare services through its hospitals. The core revenue stream is patient-care income, which includes (i) inpatient hospital services such as bed/room charges, intensive care, operating theatre and p...
Global Health Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 44.10B | 36.37B | 32.41B | 26.83B | 21.67B |
| Gross Profit | 20.95B | 27.57B | 24.82B | 20.58B | 16.24B |
| EBITDA | 10.17B | 9.05B | 8.72B | 6.77B | 4.90B |
| Net Income | 5.56B | 4.81B | 4.78B | 3.26B | 1.96B |
Balance Sheet | |||||
| Total Assets | 59.05B | 47.66B | 43.04B | 41.16B | 31.46B |
| Cash, Cash Equivalents and Short-Term Investments | 11.30B | 10.51B | 11.56B | 12.60B | 5.12B |
| Total Debt | 11.90B | 7.18B | 8.02B | 11.22B | 11.09B |
| Total Liabilities | 19.21B | 13.79B | 13.98B | 16.88B | 15.30B |
| Stockholders Equity | 39.62B | 33.86B | 29.06B | 24.28B | 16.16B |
Cash Flow | |||||
| Free Cash Flow | -2.25B | 1.07B | 3.33B | 4.09B | 367.87M |
| Operating Cash Flow | 7.53B | 6.24B | 6.12B | 6.45B | 3.11B |
| Investing Cash Flow | -11.43B | -7.21B | -4.41B | -3.42B | -4.21B |
| Financing Cash Flow | 2.87B | -972.26M | -5.14B | 3.46B | 1.60B |
Global Health Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹389.21B | 69.91 | ― | 0.07% | 21.27% | 4.09% | |
67 Neutral | ₹665.04B | 123.67 | ― | 0.52% | 15.70% | -2.76% | |
62 Neutral | ₹1.27T | 60.80 | ― | 0.23% | 17.20% | 32.79% | |
61 Neutral | ₹381.61B | 46.59 | ― | 0.24% | 57.80% | 4.07% | |
60 Neutral | ₹669.87B | 63.96 | ― | 0.11% | 17.50% | 20.65% | |
55 Neutral | ₹1.01T | 69.32 | ― | 0.19% | 15.96% | 26.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:MEDANTA
Global Health Limited
1,447.55
121.02
9.12%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,850.00
1,053.60
13.51%
IN:ASTERDM
Aster DM Healthcare Ltd.
762.95
144.85
23.43%
IN:FORTIS
Fortis Healthcare Ltd.
887.30
-88.91
-9.11%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,037.20
-135.47
-11.55%
IN:NH
Narayana Hrudayalaya Ltd.
1,867.35
99.38
5.62%
Global Health Limited Corporate Events
Global Health Reports Nil Demat Activity for June Quarter Under SEBI Rules
Jul 8, 2026
Global Health Limited has reported to BSE and NSE that, for the quarter ended June 30, 2026, its registrar and transfer agent Kfin Technologies issued certificates under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 201...
Global Health Plans Investor and Analyst Meetings in Late May 2026
May 22, 2026
Global Health Limited has scheduled meetings between its management and key institutional investors and analysts, including ICICI Prudential AMC Ltd and IIFL Capital Asset Management Limited, later in May 2026. The interactions, to be held in pers...
Global Health (Medanta) Schedules Analyst and Institutional Investor Meetings
May 22, 2026
Global Health Limited has announced that its management will hold analyst and institutional investor meetings with ICICI Prudential AMC in person in Gurugram on May 27, 2026, and with IIFL Capital Asset Management via a virtual meeting on May 28, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.